e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 9

Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study

Niklas Mattsson-Carlgren; Sebastian Palmqvist; Kanta Horie; Nicolas Barthélemy; Gemma Salvadó; Alexa Pichet Binette; Pontus Tideman; John C Morris · 2026 · The Lancet Neurology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Alzheimer's disease pathology can be accurately identified with blood biomarkers (core 1 biomarkers), including plasma p-tau217 tests. Biomarkers that change longitudinally after diagnosis (core 2 biomarkers) can increase confidence that Alzheimer's disease pathology is contributing to cognitive symptoms. Plasma eMTBR-tau243 reflects tau tangle pathology and is a promising core 2 biomarker. We aimed to examine whether, among patients positive for plasma p-tau217, plasma eMTBR-tau243 improves classification of established Alzheimer's disease and predicts cognitive decline and tau ta

Abstract by Niklas Mattsson-Carlgren; Sebastian Palmqvist; Kanta Horie; Nicolas Barthélemy; Gemma Salvadó; Alexa Pichet Binette; Pontus Tideman; John C Morris, The Lancet Neurology (2026) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/s1474-4422(26)00029-3